公开(公告)号：US12269880B2

公开(公告)日：2025-04-08

申请号：US17854227

申请日：2022-06-30

Applicant: Leidos, Inc.

Inventor： Gabriel M. Gutierrez ,  Vinayaka Kotraiah ,  Timothy W. Phares ,  James Pannucci ,  Marc Mansour

IPC: C07K7/08 ,  A61K38/04 ,  A61K38/10 ,  A61K38/16 ,  A61K39/395 ,  A61K45/06 ,  C07K14/00 ,  C07K16/28 ,  C12N15/11

Abstract: This disclosure provides nucleic acids encoding peptides which bind to LAG3 and can be used to block the interaction of LAG 3 with other molecules such as MHC-II, FGL1, and α-synuclein. These peptides can be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, or inhibiting the progression of a synucleinopathy, inhibiting the progression of sepsis, inhibiting the progression of an infectious disease, and enhancing a response to a vaccine.

公开(公告)号：US20240075131A1

公开(公告)日：2024-03-07

申请号：US18388036

申请日：2023-11-08

Applicant: Leidos, Inc.

Inventor： Gabriel M. Gutierrez ,  Vinayaka Kotraiah ,  James Pannucci ,  Ramses Ayala

IPC: A61K39/39 ,  A61K38/10 ,  A61K38/16 ,  A61K39/00 ,  A61K39/015 ,  C07K7/08

CPC classification number: A61K39/39 ,  A61K38/10 ,  A61K38/16 ,  A61K39/0011 ,  A61K39/015 ,  C07K7/08 ,  A61K2039/55516 ,  Y02A50/30

Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.

公开(公告)号：US20230414703A1

公开(公告)日：2023-12-28

申请号：US18204545

申请日：2023-06-01

Applicant: Leidos, Inc.

Inventor： Gabriel M. Gutierrez ,  Vinayaka Kotraiah ,  James Pannucci ,  Ramses Ayala

IPC: A61K38/10 ,  A61K39/015 ,  A61K38/16 ,  A61K39/00 ,  A61K35/17 ,  A61K38/19 ,  A61P33/06 ,  A61P31/20 ,  A61P37/04 ,  A61P35/04 ,  A61K45/06 ,  C07K7/08 ,  C07K14/00 ,  A61K39/39

CPC classification number: A61K38/10 ,  A61K39/015 ,  A61K38/16 ,  A61K39/0011 ,  A61K35/17 ,  A61K38/19 ,  A61P33/06 ,  A61P31/20 ,  A61P37/04 ,  A61P35/04 ,  A61K45/06 ,  C07K7/08 ,  C07K14/00 ,  A61K39/39 ,  A61K48/00

Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.

公开(公告)号：US20220395554A1

公开(公告)日：2022-12-15

申请号：US17854227

申请日：2022-06-30

Applicant: Leidos, Inc.

Inventor： Gabriel M. Gutierrez ,  Vinayaka Kotraiah ,  Timothy W. Phares ,  James Pannucci ,  Marc Mansour

IPC: A61K38/10 ,  C07K7/08 ,  A61K45/06

Abstract: This disclosure provides peptides which bind to LAG3, such as SAPWEPLHWPEDWWQGTGEW (SEQ ID NO:1), and can be used to block the interaction of LAG 3 with other molecules such as MHC-II, FGL1, and α-synuclein. These peptides can be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, or inhibiting the progression of a synucleinopathy, inhibiting the progression of sepsis, inhibiting the progression of an infectious disease, and enhancing a response to a vaccine.

公开(公告)号：US11338040B2

公开(公告)日：2022-05-24

申请号：US17337489

申请日：2021-06-03

Applicant: Leidos, Inc.

Inventor： Gabriel M. Gutierrez ,  James Pannucci ,  Vinayaka Kotraiah ,  Timothy W. Phares ,  Cecille D. Browne

IPC: A61K38/10 ,  C07K7/08 ,  A61K47/62 ,  A61K47/60

Abstract: This disclosure provides peptide conjugates that are useful for inhibiting the progression of a hyperproliferative disorder, inhibiting the progression of sepsis, inhibiting the progression of an infectious disease, enhancing a response to a vaccine, or inhibiting the progression of a synucleinopathy.

公开(公告)号：US20210000948A1

公开(公告)日：2021-01-07

申请号：US17026447

申请日：2020-09-21

Applicant: Leidos, Inc.

Inventor： Gabriel M. Gutierrez ,  Vinayaka Kotraiah ,  James Pannucci ,  Ramses Ayala

IPC: A61K39/39 ,  A61K38/10 ,  C07K7/08 ,  A61K38/16 ,  A61K39/00 ,  A61K39/015

Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.

公开(公告)号：US11793856B2

公开(公告)日：2023-10-24

申请号：US17015658

申请日：2020-09-09

Applicant: Leidos, Inc.

Inventor： Gabriel M. Gutierrez ,  Vinayaka Kotraiah ,  James Pannucci ,  Ramses Ayala

IPC: A61K38/10 ,  A61K39/015 ,  A61K38/16 ,  A61K39/00 ,  A61K35/17 ,  A61K38/19 ,  A61P33/06 ,  A61P31/20 ,  A61P37/04 ,  A61P35/04 ,  A61K45/06 ,  C07K7/08 ,  C07K14/00 ,  A61K39/39 ,  A61K48/00

CPC classification number: A61K38/10 ,  A61K35/17 ,  A61K38/16 ,  A61K38/19 ,  A61K39/0011 ,  A61K39/015 ,  A61K39/39 ,  A61K45/06 ,  A61P31/20 ,  A61P33/06 ,  A61P35/04 ,  A61P37/04 ,  C07K7/08 ,  C07K14/00 ,  A01K2227/105 ,  A01K2267/0331 ,  A01K2267/0337 ,  A61K48/00

Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.

公开(公告)号：US11578102B2

公开(公告)日：2023-02-14

申请号：US17386637

申请日：2021-07-28

Applicant: Leidos, Inc.

Inventor： Gabriel M. Gutierrez ,  James Pannucci ,  Vinayaka Kotraiah ,  Timothy W. Phares ,  Cecilie D. Browne

IPC: C07K7/08 ,  A61K38/10 ,  A61K45/06

Abstract: This disclosure provides peptides that bind to LAG3 and can be used to block its interaction with other molecules such as MHC-II, FGL1, and α-synuclein. These peptides, with their demonstrated activity and short half-life, can be used to activate cellular immunity while significantly reducing the potential for adverse events that is often associated with the antibody-based checkpoint inhibitors. The peptides can be used as stand-alone therapeutics or can be used as immune modulators in combination with other therapies.

公开(公告)号：US20210379189A1

公开(公告)日：2021-12-09

申请号：US17337489

申请日：2021-06-03

Applicant: Leidos, Inc.

Inventor： Gabriel M. Gutierrez ,  James Pannucci ,  Vinayaka Kotraiah ,  Timothy W. Phares ,  Cecille D. Browne

IPC: A61K47/62 ,  A61K38/10 ,  A61K47/60

Abstract: This disclosure provides peptide conjugates that are useful for inhibiting the progression of a hyperproliferative disorder, inhibiting the progression of sepsis, inhibiting the progression of an infectious disease, enhancing a response to a vaccine, or inhibiting the progression of a synucleinopathy.

公开(公告)号：US20180185474A1

公开(公告)日：2018-07-05

申请号：US15908861

申请日：2018-03-01

Applicant: Leidos, Inc.

Inventor： Gabriel M. Gutierrez ,  Vinayaka Kotraiah ,  James Pannucci ,  Ramses Ayala

IPC: A61K39/39 ,  C07K7/08 ,  A61K39/015 ,  A61K38/10 ,  A61K39/00 ,  A61K38/16

Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.